

# Alo Nag

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6431265/publications.pdf>

Version: 2024-02-01

29  
papers

734  
citations

516710

16  
h-index

526287

27  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1012  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Xeroderma Pigmentosum Group E Gene Product DDB2 Is a Specific Target of Cullin 4A in Mammalian Cells. <i>Molecular and Cellular Biology</i> , 2001, 21, 6738-6747.	2.3	152
2	FoxM1: Repurposing an oncogene as a biomarker. <i>Seminars in Cancer Biology</i> , 2018, 52, 74-84.	9.6	98
3	An Essential Role of Human Ada3 in p53 Acetylation. <i>Journal of Biological Chemistry</i> , 2007, 282, 8812-8820.	3.4	45
4	DDB2 Induces Nuclear Accumulation of the Hepatitis B Virus X Protein Independently of Binding to DDB1. <i>Journal of Virology</i> , 2001, 75, 10383-10392.	3.4	39
5	Assessment of Targeting Potential of Galactosylated and Mannosylated Sterically Stabilized Liposomes to Different Cell Types of Mouse Liver. <i>Journal of Drug Targeting</i> , 1999, 6, 427-438.	4.4	36
6	Human ADA3 Binds to Estrogen Receptor (ER) and Functions As a Coactivator for ER-mediated Transactivation. <i>Journal of Biological Chemistry</i> , 2004, 279, 54230-54240.	3.4	35
7	Significance of human microbiome in breast cancer: Tale of an invisible and an invincible. <i>Seminars in Cancer Biology</i> , 2021, 70, 112-127.	9.6	35
8	Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 1125-1140.	1.6	34
9	Ada3 Requirement for HAT Recruitment to Estrogen Receptors and Estrogen-Dependent Breast Cancer Cell Proliferation. <i>Cancer Research</i> , 2007, 67, 11789-11797.	0.9	32
10	Mammalian Alteration/Deficiency in Activation 3 (Ada3) Is Essential for Embryonic Development and Cell Cycle Progression. <i>Journal of Biological Chemistry</i> , 2012, 287, 29442-29456.	3.4	27
11	Long circulatory liposomal maduramicin inhibits the growth of <i>Plasmodium falciparum</i> blood stages in culture and cures murine models of experimental malaria. <i>Nanoscale</i> , 2018, 10, 13773-13791.	5.6	25
12	Oncogenic Human Papillomavirus 16E7 modulates SUMOylation of FoxM1b. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 58, 28-36.	2.8	21
13	Exploring the therapeutic potential of forkhead box O for outfoxing COVID-19. <i>Open Biology</i> , 2021, 11, 210069.	3.6	21
14	Peroxisome Proliferator Activated Receptor Gamma Sensitizes Non-small Cell Lung Carcinoma to Gamma Irradiation Induced Apoptosis. <i>Frontiers in Genetics</i> , 2019, 10, 554.	2.3	20
15	DNA damage induced activation of Cygb stabilizes p53 and mediates G1 arrest. <i>DNA Repair</i> , 2014, 24, 107-112.	2.8	19
16	Cytoglobin in tumor hypoxia: novel insights into cancer suppression. <i>Tumor Biology</i> , 2014, 35, 6207-6219.	1.8	18
17	High-risk HPV16E6 stimulates hADA3 degradation by enhancing its SUMOylation. <i>Carcinogenesis</i> , 2014, 35, 1830-1839.	2.8	17
18	The pint- sized powerhouse: Illuminating the mighty role of the gut microbiome in improving the outcome of anti- cancer therapy. <i>Seminars in Cancer Biology</i> , 2021, 70, 98-111.	9.6	12

#	ARTICLE	IF	CITATIONS
19	Ionophores as Potent Anti-malarials: A Miracle in the Making. <i>Current Topics in Medicinal Chemistry</i> , 2019, 18, 2029-2041.	2.1	10
20	Cell cycle-dependent regulation of cytoglobin by Skp2. <i>FEBS Letters</i> , 2017, 591, 3507-3522.	2.8	9
21	PPAR $\beta$ -targeting Potential for Radioprotection. <i>Current Drug Targets</i> , 2018, 19, 1818-1830.	2.1	8
22	Identification of genetic variants in TNF receptor 2 which are associated with the development of cervical carcinoma. <i>Biomarkers</i> , 2016, 21, 665-672.	1.9	6
23	Artemisinin Mediates Its Tumor-Suppressive Activity in Hepatocellular Carcinoma Through Targeted Inhibition of FoxM1. <i>Frontiers in Oncology</i> , 2021, 11, 751271.	2.8	5
24	Repurposing the Pathogen Box compounds for identification of potent anti-malarials against blood stages of <i>Plasmodium falciparum</i> with PfUCLH3 inhibitory activity. <i>Scientific Reports</i> , 2022, 12, 918.	3.3	4
25	Tale of a multifaceted co-activator, hADA3: from embryogenesis to cancer and beyond. <i>Open Biology</i> , 2016, 6, 160153.	3.6	3
26	Phe <sup>28</sup> B <sup>10</sup> Induces Channel-Forming Cytotoxic Amyloid Fibrillation in Human Neuroglobin, the Brain-Specific Hemoglobin. <i>Biochemistry</i> , 2016, 55, 6832-6847.	2.5	1
27	Identification of a peptide that disrupts hADA3-E6 interaction with implications in HPV induced cancer therapy. <i>Life Sciences</i> , 2022, 288, 120157.	4.3	1
28	The anaphase-promoting complex/cyclosome co-activator, Cdh1, is a novel target of human papillomavirus 16 E7 oncoprotein in cervical oncogenesis. <i>Carcinogenesis</i> , 2022, 43, 988-1001.	2.8	1
29	Identification of novel interaction between Promyelocytic Leukemia protein and human Alteration/Deficiency in Activation 3 coactivator and its role in DNA damage response. <i>Journal of Proteins and Proteomics</i> , 2019, 10, 207-220.	1.5	0